Article
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.
Hepatology (Baltimore, Md.) - 1 Jun 2014
Rembeck Karolina, Waldenström Jesper, Hellstrand Kristoffer, Nilsson Staffan, Nyström Kristina, Martner Anna, Lindh Magnus, Norkrans Gunnar, Westin Johan, Pedersen Court, Färkkilä Martti, Langeland Nina, Buhl Mads Rauning, Mørch Kristine, Christensen Peer Brehm, Lagging Martin
Abstract excerpt
UNLABELLED: The present study evaluated the impact of variations in the inosine triphosphate pyrophosphatase (ITPase) gene (ITPA) on treatment outcome in patients with hepatitis C virus (HCV) genotype 2/3 infection receiving peginterferon-α2a and lower, conventional 800 mg daily dose of ribavirin. Previous studies using higher, weight-based ribavirin dosing report that patients carrying polymorphisms encoding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
